21 May WisBusiness: Cellectar Biosciences is expanding one of the cohorts in an ongoing clinical study of the Madison company’s cancer therapy
The move comes after Cellectar announced initial results from an ongoing Phase 2 clinical study, which “exceeded its pre-specified performance criteria.” Because of that, the company will enroll more patients with various types of cancer.
According to a release, Cellectar plans to report results from the study later this year.
The company’s cancer therapy is being tested at 10 different cancer centers around the country in patients with cancers of the blood.
See the full article here.